BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 1740583)

  • 1. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
    Müller U; Helbling A; Berchtold E
    J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
    Bilò MB; Severino M; Cilia M; Pio A; Casino G; Ferrarini E; Campodonico P; Milani M
    Ann Allergy Asthma Immunol; 2009 Jul; 103(1):57-61. PubMed ID: 19663128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Honeybee and wasp venom allergy: Sensitization and immunotherapy.
    Adib-Tezer H; Bayerl C
    J Dtsch Dermatol Ges; 2018 Oct; 16(10):1228-1247. PubMed ID: 30300499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy.
    Blaauw PJ; Smithuis OL; Elbers AR
    J Allergy Clin Immunol; 1996 Jul; 98(1):39-47. PubMed ID: 8765816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
    Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
    Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
    J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A; Yogev A; Confino-Cohen R
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy.
    Kochuyt AM; Stevens EA
    Clin Exp Allergy; 1994 Jan; 24(1):35-41. PubMed ID: 8156444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
    Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
    J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Wasp and bee venom allergy].
    Knulst AC; de Maat-Bleeker F; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 1998 Apr; 142(16):889-92. PubMed ID: 9623183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature.
    Diwakar L; Noorani S; Huissoon AP; Frew AJ; Krishna MT
    Clin Exp Allergy; 2008 Oct; 38(10):1651-8. PubMed ID: 18727621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors.
    Birnbaum J; Ramadour M; Magnan A; Vervloet D
    Clin Exp Allergy; 2003 Jan; 33(1):58-64. PubMed ID: 12534550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
    Sturm G; Kränke B; Rudolph C; Aberer W
    J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bee and wasp venom allergy in Turkey.
    Kalyoncu AF; Demir AU; Ozcan U; Ozkuyumcu C; Sahin AA; Bariş YI
    Ann Allergy Asthma Immunol; 1997 Apr; 78(4):408-12. PubMed ID: 9109709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rush hyposensitization with Hymenoptera venoms. Tolerance and results of therapy].
    Przybilla B; Ring J; Griesshammer B; Braun-Falco O
    Dtsch Med Wochenschr; 1987 Mar; 112(11):416-24. PubMed ID: 3816590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?
    Sahiner UM; Durham SR
    Front Immunol; 2019; 10():1959. PubMed ID: 31497015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.